Source: Asian Venture Capital Journal

ABclonal: China's ABclonal Technology raises $189m

Chinese life science research and diagnostic reagents provider ABclonal Technology has raised a RMB1.2 billion ($189 million) Series D round featuring Sequoia Capital China.

Read full article »

ABclonal's Competitors | ABclonal's News | ABclonal's Financials

Followers on Owler

Est. Annual Revenue

$5.0-25M

Est. Employees

100-250

CEO

Wu Zack

CEO Approval Rating

90/100

ABclonal is a China-based biotechnology company that researches and develops antibodies and molecular enzyme products for industries such as life science and pharmaceuticals.